(Q48627896)

13 February 2018

title

1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. (English)

1 reference

13 February 2018

4

Valérie Rigau

1 reference

13 February 2018

author name string

Catherine Gozé

1

1 reference

13 February 2018

Charlotte Bezzina

2

1 reference

13 February 2018

Eric Gozé

3

1 reference

13 February 2018

Thierry Maudelonde

5

1 reference

13 February 2018

Luc Bauchet

6

1 reference

13 February 2018

Hugues Duffau

7

1 reference

13 February 2018

publication date

6 March 2012

1 reference

13 February 2018

Journal of Neuro-Oncology

published in

1 reference

13 February 2018

volume

108

1 reference

13 February 2018

issue

1

1 reference

13 February 2018

page(s)

69-75

1 reference

13 February 2018

https://scigraph.springernature.com/pub.10.1007/s11060-012-0831-6

exact match

0 references

cites work

An integrated genomic analysis of human glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Molecular classification of low-grade diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Continuous growth of mean tumor diameter in a subset of grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Prognostic stratification of patients with anaplastic gliomas according to genetic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Dynamic history of low-grade gliomas before and after temozolomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

A simple salting out procedure for extracting DNA from human nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

p53 protein accumulation and gene mutations in human glioma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Glioma IDH1 mutation patterns off the beaten track.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas

21 January 2018

1 reference

12 December 2020

Comparative study of p53 gene and protein alterations in human astrocytic tumors

1 reference

12 December 2020

Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects

1 reference

12 December 2020

Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.

1 reference

12 December 2020

Robust Regression: Asymptotics, Conjectures and Monte Carlo

1 reference

19 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.1214/AOS/1176342503

Identifiers

DOI

10.1007/S11060-012-0831-6

1 reference

13 February 2018

1 reference

13 February 2018